Alectinib D6

Alectinib D6 is a deuterated form of Alectinib, a drug used in the treatment of non-small cell lung cancer (NSCLC) that has spread to other parts of the body. Alectinib D6 is a tyrosine kinase inhibitor that works by blocking the action of anaplastic lymphoma kinase (ALK), a protein that promotes the growth and spread of cancer cells. By inhibiting ALK, Alectinib D6 helps to slow down or stop the growth of cancer cells, thereby improving the patient's chances of survival. In terms of its chemical properties, Alectinib D6 is a white to off-white powder with a molecular weight of 555.67 g/mol. It is slightly soluble in water and has a melting point of 184-187°C. Alectinib D6 is also known by its chemical name, (R)-1-(2,6-dichloro-3-fluorophenyl)-2-[(1-methylpiperidin-4-yl)amino]-1-(4-(4-deuterium-labeled-phenyl)piperidin-4-yl)ethanol. Alectinib D6 is typically administered orally in capsule form, and the dosage and duration of treatment may vary depending on the patient's age, weight, and overall health status. Common side effects of Alectinib D6 include fatigue, nausea, diarrhea, and muscle pain. Patients taking this medication should also be monitored for potential liver and kidney problems, as well as any signs of allergic reactions or other serious adverse effects. Overall, Alectinib D6 is an important drug in the fight against NSCLC, and its deuterated form may offer enhanced therapeutic benefits compared to the non-deuterated version.